A Sudden Change in the Properties of a Drug As a New Polymorph Appears Can Be Highly Damaging for Pharma Firms
Total Page:16
File Type:pdf, Size:1020Kb
Technology focus The shape shifters A sudden change in the properties of a drug as a new polymorph appears can be highly damaging for pharma firms. The industry now appears to be in control of the situation and is even reaping financial rewards from new polymorphs, as Susan Aldridge discovers The pharmaceutical industry solid state properties for the – a crucial consideration when faces a deadly and swift saboteur. In short pharmaceutical and biotechnology shipping a pharmaceutical or food This attacker hits unexpectedly Polymorphism, when industries. ‘The worst that can product. The US Food and Drug and comes under the title compounds adopt happen for a pharmaceutical Administration (FDA) thinks ‘polymorphism’: when compounds more than one crystal company is if a new polymorph these issues important enough to adopt more than one crystal structure, is taken very suddenly appears in the temperature require companies to register the structure or polymorph in the seriously by the pharma and humidity conditions of a blister polymorphic forms of any new drug solid state. A new polymorph industry pack when a compound is actually they make. can be catastrophic; overnight a A new polymorph on the market.’ It is likely that all small organic drug manufactured for market can appear suddenly in Polymorphism was first molecules have the potential for can become less soluble and less a manufactured drug, discovered in 1821 by the German polymorphism, because there are bioavailable. Although a compound’s with devastating results. chemist Eilhard Mitscherlich and so many ways in which molecules polymorphs are chemically Although chemically is a widespread phenomenon in the can be packed within a crystal, identical, their physical properties identical, the new chemical world. Polymorphs differ mainly through different ways of can be tremendously different. polymorph can have in their outer form (habit) as well arranging hydrogen bonds between ‘Polymorphism is completely very different physical as their inner structure (form). For neighbouring molecules. unpredictable,’ says Chris Frampton, properties example, polymorphs of the amino ‘It is a matter of finding the right chief scientific officer of SAFC- It is estimated that acid glycine exist either as prisms or conditions for a polymorph to form,’ Pharmorphix, a Cambridge, UK- 30–50 per cent of as a pencil shape, while paracetamol explains Frampton. Sometimes these based company which investigates pharma compounds crystals may appear as prisms or conditions may be so extreme – very exhibit polymorphism monoliths (see fig, p68). Polymorphs high pressure, for instance – that the Polymorphs are may differ in melting point, polymorph’s existence is likely to patentable and can be solubility, density, hardness, and in remain undiscovered indefinitely. A used to extend the life of optical and electrical properties. In drug or food product is made many a drug industrial terms, these differences times over; any changes in synthesis may affect manufacturing and conditions, however subtle, may processing properties, shelf life, encourage the emergence of new texture, stability against air and light, polymorphic forms. ‘We want to ability to be compressed into a tablet, ensure the crystallisation step yields and so on. the same polymorph each time,’ says The first polymorph to form may Frampton. be metastable and liable to convert Roland Boese, of the University of to a different, more stable, form over Duisberg-Essen, Germany, quotes time or under different conditions estimates that 30 to 50 per cent of re-synthesis. Or the most stable of pharmaceutically important polymorph at room temperature compounds exhibit polymorphism. may become metastable at another If hydrates and solvates are included, Chemist Eilhard temperature; transitions between then perhaps as many as 90 per cent Mitscherlich discovered polymorphs may occur as the of compounds will exist in more than polymorphism in 1821 temperature is raised or lowered one crystalline form. 64 | Chemistry World | April 2007 www.chemistryworld.org CW.04.07.polymorphs.indd 64 21/03/2007 08:25:41 PHARMORPHIX www.chemistryworld.org Chemistry World | April 2007 | 65 CW.04.07.polymorphs.indd 65 21/03/2007 08:26:13 Technology focus Now polymorph screening is a common procedure, using robots to carry out hundreds or thousands PHARMORPHIX of crystallisation experiments using different solvents or solvent mixtures and different cooling and evaporation rates. Boese, one of the international team that analysed aspirin’s form II, adds that some scientists still discover polymorphs using a more empirical approach. ‘There is no general rule, but some more or less intuitive guidelines do exist, sometimes kept secret by experimentalists.’ A stable polymorph is obviously a potentially good choice for a pharmaceutical company to take into further development. But stability is not the only consideration. ‘A metastable form may have better dissolution properties, which then improves the bioavailability,’ says Boese. ‘But the metastable form may then transform into the stable form, which is then less soluble. This was the case with ritonavir.’ On the other hand, as Frampton points out, a compound can be too soluble – it may take in water during storage. Once a desired polymorph has been discovered, the next step is to learn how to obtain it reliably – and stop less desired polymorphs from forming. The crystallisation process is not well understood Industrial cost form II exclusively. This involved X-ray crystallography but involves nuclei forming In industry, the existence of a carefully controlled reflux and is crucial in the hunt for within a supersaturated solution polymorphs is best discovered cooling cycle, keeping the solutions new polymorphs of the compound. The nuclei act sooner rather than later, as US and reactor as free as possible from as templates for the formation pharmaceutical firm Abbott form II contamination. of further crystals within the Laboratories learnt to its cost. In Even long-established drugs can solution. Without nucleation, the 1998 the company found that it be hit by polymorphism. In 2005, a supersaturated solution may not could no longer make the original team of researchers led by Michael crystallise for a long time, which form of its HIV drug ritonavir Zaworotko of the University of is why chemists sometimes try to because a second polymorph had South Florida, US, claimed to form nuclei by scratching the side taken the place of the first during have discovered and made a new of the vessel containing the solution manufacture. Abbott scientists polymorph of aspirin: form II (see with a glass rod. Tiny crystals of had discovered that the drug was fig, p70). Then, last year, a team from the desired polymorph – if they starting to fail dissolution tests Denmark, Germany and India, led exist – can act as nuclei or seeds for and precipitating out of capsules. by Boese, claimed to show that the crystallising that polymorph. But Investigation showed the existence crystals analysed by the US team seeding doesn’t always work as of polymorph II (needles), which were in fact an intergrowth of two planned – if seeds of an undesired was more soluble and less stable polymorphs: form I and form II. polymorph are present, even in a than polymorph I (rods). Form II Pure form II is elusive, they say. very small amount, they will tend soon spread and form I could no ‘It is the worst to seed that polymorph, instead of longer be synthesised. Form II’s Structure screening the wanted one. Impurities can also decreased solubility could have Ritonavir served as a wake-up call that can happen act as seeds. ‘The purer a compound affected the drug’s bioavailability for the pharmaceutical industry, for a pharma is the less likely templating is. As and Abbott was forced to withdraw which became more interested in a compound becomes purer, there ritonavir from the market for a time exploring the solid state of drug company if a could be a switch to a different while it figured out how to get the candidates at an earlier stage. new polymorph polymorph,’ says Bill Jones, head original polymorph back; its loss Previously, companies had been of the chemistry department at in sales was compounded by extra reluctant to part with precious suddenly Cambridge University, UK. development costs. Abbott scientists milligrams of a new compound for appears when Crystallisation need not be so finally found a way to get back, these studies – especially when unpredictable. Recent research from consistently, to form I while also they might not even go ahead with a drug is on the Mike Ward’s group at the University discovering a way to manufacture developing the compound. market’ of Minnesota, US, suggests that the 66 | Chemistry World | April 2007 www.chemistryworld.org CW.04.07.polymorphs.indd 66 21/03/2007 08:26:47 2112-25 Chme World (Pharmorphix) 275x210 Ad 15/3/07 12:00 Page 1 Pharmorphix™ Solid State Chemistry Accelerating drug development. Strengthening Intellectual Property. Extending product life. Pharmorphix is a world leading provider of solid form research services to the pharmaceutical and biotechnology sectors. Our experience coupled with state of the art facilities, places Pharmorphix at the forefront of pharmaceutical solid form research and development. Our focus is to drive molecules into the clinic by understanding and modifying the physical properties of the drug substance to ensure patient benefit, rapid development and protection of intellectual property. Pharmorphix's R&D support services include polymorph investigation, salt selection, physicochemical property determinations, pre-formulation profiling, co crystal investigations, classical chiral resolution and crystallization studies. For solid state chemistry services beyond expectation – look to SAFC Pharma. www.chemistryworld.org Chemistry World | April 2006 | 67 www.safc-pharmorphix.com Member of the Sigma-Aldrich Group CW Adverts_Display.indd 67 20/03/2007 15:37:52 Technology focus How many polymorphs? Many compounds such as sucrose polymorphism was discovered and naphthalene appear to have by Lian Yu, now of the University only one polymorphic form.